Sheng Wang, Li Xiaoyu, Li Jiayi, Mi Yanjun, Li Fan
Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Department of Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
J Gastrointest Oncol. 2021 Aug;12(4):1228-1240. doi: 10.21037/jgo-21-371.
Tumor microenvironment (TME) cells are an important part of tumor tissues. There is increasing evidence that the TME plays a vital role in tumor prognosis, and is associated with patient survival in various kinds of malignances. To date, very little research has been conducted on how to effectively use TME to better evaluate the prognosis of patients with esophageal carcinoma (EC). The concept of a "TME score" was introduced to better distinguish the prognosis of patients.
We employed bioinformatic methods to investigate the TME infiltration patterns of 160 patients with EC from the Cancer Genome Atlas (TCGA) cohort. TME clusters were identified using k-means clustering methods with 1,000 resampling times. The significance of the survival difference among patients belonging to different TME clusters was assessed by the log-rank test and Kaplan-Meier survival curves. Correlations between immune cell types and survival were calculated by a Cox regression, and the Pearson correlation coefficient (PCC) was used to measure the relationship among different immune cell types. We classified patient into 2 subtypes based on the optimal breakpoint of TME score determined by R package maxstat.
Two TME phenotypes were defined based on the immune cell type fractions, and patients with a high TME score phenotype had a better prognosis than those with a low TME score phenotype. Kaplan-Meier analysis for differentially expressed micro ribonucleic acids (RNAs) and messenger RNAs also showed that different TME score subtypes were significantly associated with the prognosis of EC. Just as tumor mutational burden can predict the efficacy of immunotherapy, the TME score can predict the efficacy of immune checkpoint inhibitors (ICIs). The genomic alterations of 2 TME score subtypes of EC further revealed that genomic instability is prevalent in TMEs, and patients with a low TME score subtype have a more unstable chromosome status than those with a high subtype.
Thus, TME score is an emerging prognostic biomarker for predicting the efficacy of ICIs.
肿瘤微环境(TME)细胞是肿瘤组织的重要组成部分。越来越多的证据表明,TME在肿瘤预后中起着至关重要的作用,并且与各种恶性肿瘤患者的生存相关。迄今为止,关于如何有效利用TME来更好地评估食管癌(EC)患者预后的研究非常少。引入了“TME评分”的概念以更好地区分患者的预后。
我们采用生物信息学方法研究来自癌症基因组图谱(TCGA)队列的160例EC患者的TME浸润模式。使用k均值聚类方法进行1000次重采样来识别TME簇。通过对数秩检验和Kaplan-Meier生存曲线评估不同TME簇患者生存差异的显著性。通过Cox回归计算免疫细胞类型与生存之间的相关性,并使用Pearson相关系数(PCC)来衡量不同免疫细胞类型之间的关系。我们根据R包maxstat确定的TME评分的最佳断点将患者分为2个亚型。
根据免疫细胞类型分数定义了两种TME表型,TME高评分表型的患者比TME低评分表型的患者预后更好。对差异表达的微小核糖核酸(RNA)和信使RNA的Kaplan-Meier分析也表明,不同的TME评分亚型与EC的预后显著相关。正如肿瘤突变负荷可以预测免疫治疗的疗效一样,TME评分可以预测免疫检查点抑制剂(ICI)的疗效。EC的2种TME评分亚型的基因组改变进一步揭示,基因组不稳定性在TME中普遍存在,TME低评分亚型的患者比高评分亚型的患者具有更不稳定的染色体状态。
因此,TME评分是一种新兴的预后生物标志物,可用于预测ICI的疗效。